Last reviewed · How we verify
Early intravenous tranexamic acid administration
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding in acute trauma and hemorrhage.
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding in acute trauma and hemorrhage. Used for Acute traumatic hemorrhage (early intravenous administration), Reduction of blood loss and transfusion requirements in trauma patients.
At a glance
| Generic name | Early intravenous tranexamic acid administration |
|---|---|
| Also known as | tranexamic acid administration, transamine administration, antifibrinolytics administration |
| Sponsor | Seoul National University Hospital |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Trauma / Hemorrhage / Emergency Medicine |
| Phase | Phase 3 |
Mechanism of action
Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, preventing the breakdown of fibrin clots. Early intravenous administration in acute hemorrhage settings aims to reduce mortality and transfusion requirements by stabilizing clot formation during the critical early phase of injury.
Approved indications
- Acute traumatic hemorrhage (early intravenous administration)
- Reduction of blood loss and transfusion requirements in trauma patients
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Seizures
- Visual disturbances
- Gastrointestinal disturbances
Key clinical trials
- Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis (PHASE3)
- Tranexamic Acid with Intensive Blood Pressure Management in Ultra-Early Intracerebral Hemorrhage (PHASE4)
- Tranexamic Acid in Sleeve Gastrectomy (NA)
- Efficacy of Tranexamic Acid in Upper Gastrointestinal Bleeding (PHASE3)
- Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial (PHASE3)
- Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding (PHASE4)
- Tranexamic Acid for Upper Gastrointestinal Bleeding (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: